parkinson's disease - Search News

Black Sabbath to reunite amid frontman's Parkinson's disease

Hosted on MSN · 3h

Ozzy Osbourne's Parkinson's disease 'affected his legs,' Sharon says as his last show looms

Heavy metal star Ozzy Osbourne reveals the date for his final show, which will also reunite the founding members of Black Sabbath after 20 years.

USA TODAY on MSN · 7h

Ozzy Osbourne's final show: Black Sabbath to reunite amid frontman's Parkinson's disease

Ozzy Osbourne will come out of touring retirement and reunite with the full Black Sabbath lineup for the first time in 20 years.

Newsweek on MSN · 2d

Ozzy Osbourne to Hit the Stage With Black Sabbath Amid Debilitating Parkinson's Battle

Black Sabbath will be reuniting for a performance in Ozzy Osbourne's hometown of Birmingham, U.K.. Osbourne, 76, has been battling Parkinson's disease for years, but the Prince of Darkness will not let that keep him from the stage.

Daniel Barenboim, Parkinson's disease

The Washington Post · 1d

Conductor Daniel Barenboim says he's been diagnosed with Parkinson's disease

Conductor Daniel Barenboim says he has been diagnosed with Parkinson’s disease. The 82-year-old issued a statement Thursday on Instagram. He has appeared more frail since 2022, canceling scheduled performances that included a new production of Wagner’s Ring Cycle in Berlin.

The New York Times · 1d

Daniel Barenboim Announces He Has Parkinson’s Disease

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, said Thursday that he has Parkinson’s disease.

Chicago Sun-Times · 1d

Conductor Daniel Barenboim reveals his Parkinson's disease diagnosis

The maestro has appeared more frail since 2022, canceling scheduled performances that included a new production of Wagner's Ring Cycle in Berlin.

Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

3d

U.S. FDA approves Supernus' drug-device combination for Parkinson's disease

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

Study Finds Exenatide Not Beneficial for Parkinson Disease

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

1d

FDA approves wearable infusion device for advanced Parkinson disease

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

GLP-1 does not slow Parkinson’s disease progression in phase 3 study

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A breakthrough in Parkinson’s disease detection

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

MedPage Today1d

Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results